These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31646838)

  • 1. Thymidylate synthase expression at metastatic site might be more correlated with response to anti-thymidylate synthase agent in triple negative breast cancers.
    Altundag K
    J BUON; 2019; 24(4):1737. PubMed ID: 31646838
    [No Abstract]   [Full Text] [Related]  

  • 2. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
    Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
    Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
    [No Abstract]   [Full Text] [Related]  

  • 3. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei D; Groshen S; Lenz HJ
    Int J Colorectal Dis; 2002 Jan; 17(1):46-9. PubMed ID: 12018454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase and drug resistance.
    Peters GJ; van der Wilt CL; van Triest B; Codacci-Pisanelli G; Johnston PG; van Groeningen CJ; Pinedo HM
    Eur J Cancer; 1995; 31A(7-8):1299-305. PubMed ID: 7577040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase expression in colorectal cancer: the never-ending story.
    Vincenzi B; Santini D; Tonini G
    J Clin Oncol; 2005 Mar; 23(9):2108; author reply 2108-9. PubMed ID: 15774806
    [No Abstract]   [Full Text] [Related]  

  • 6. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
    Papamichael D
    Oncologist; 1999; 4(6):478-87. PubMed ID: 10631692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric Oxide Inhibitors Hit Target for Triple-Negative Breast Cancer.
    Firger J
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243205
    [No Abstract]   [Full Text] [Related]  

  • 8. Thymidylate synthase structure, function and implication in drug discovery.
    Costi MP; Ferrari S; Venturelli A; Calò S; Tondi D; Barlocco D
    Curr Med Chem; 2005; 12(19):2241-58. PubMed ID: 16178783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase inhibitors.
    Takimoto CH; Diggikar S
    Cancer Chemother Biol Response Modif; 2005; 22():1-18. PubMed ID: 16110605
    [No Abstract]   [Full Text] [Related]  

  • 10. Thymidylate synthase inhibitors.
    Ackland SP; Clarke SJ; Beale P; Peters GJ
    Cancer Chemother Biol Response Modif; 2002; 20():1-36. PubMed ID: 12703198
    [No Abstract]   [Full Text] [Related]  

  • 11. Experience with eribulin in triple-negative metastatic breast cancer: case studies.
    Gallegos Sancho MI; Márquez-Vázquez R; Sánchez-Muñoz A
    Future Oncol; 2018 Mar; 14(7s):13-20. PubMed ID: 29611754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase inhibitors.
    Ackland SP; Beale P; Peters GJ
    Cancer Chemother Biol Response Modif; 2003; 21():1-28. PubMed ID: 15338738
    [No Abstract]   [Full Text] [Related]  

  • 13. Thymidylate synthase inhibitors.
    Ismail AS; Grem JL
    Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
    [No Abstract]   [Full Text] [Related]  

  • 14. Androgen receptor-positive, triple-negative breast cancer.
    Gucalp A; Traina TA
    Cancer; 2017 May; 123(10):1686-1688. PubMed ID: 28406524
    [No Abstract]   [Full Text] [Related]  

  • 15. Thymidylate synthase: a critical target for cancer chemotherapy.
    Rose MG; Farrell MP; Schmitz JC
    Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.
    Soo RA; Syn N; Lee SC; Wang L; Lim XY; Loh M; Tan SH; Zee YK; Wong AL; Chuah B; Chan D; Lim SE; Goh BC; Soong R; Yong WP
    Sci Rep; 2016 Jun; 6():27826. PubMed ID: 27296624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase inhibitors in colorectal cancer.
    Cassidy J
    Semin Oncol; 2000 Oct; 27(5 Suppl 10):83-7. PubMed ID: 11049037
    [No Abstract]   [Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
    Li XY; Liang JW; Mohamed O K; Zhang TJ; Lu GQ; Meng FH
    Eur J Med Chem; 2018 Jun; 154():267-279. PubMed ID: 29807332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the expression of CD44, apoptosis and thymidylate synthase inhibition rate correlate with the efficacy of chemotherapy in colorectal cancer?
    Tachikawa D; Arima S; Futami K; Iwashita A
    Anticancer Res; 2000; 20(1C):595-600. PubMed ID: 10769701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impressive Response to Capecitabine in a Patient with Obstructive Jaundice due to Metastatic Triple-Negative Breast Cancer.
    Sattwika PD; Oktariani S; Leo B; Sagiran ; Iqbal M; Choridah L; Bayupurnama P; Kurnianda J; Hutajulu SH
    Oncol Res Treat; 2019; 42(11):607-611. PubMed ID: 31557756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.